Literature DB >> 26526907

In situ dsDNA-bevacizumab anticancer monoclonal antibody interaction electrochemical evaluation.

Luciana I N Tomé1, Nuno V Marques2, Victor C Diculescu1, Ana Maria Oliveira-Brett3.   

Abstract

The interaction of the anticancer monoclonal antibody bevacizumab (BEVA) with double-stranded DNA (dsDNA) was studied by voltammetry and gel-electrophoresis in incubated samples and using the dsDNA-electrochemical biosensor. The voltammetric results revealed a decrease and disappearance of the dsDNA oxidation peaks with increasing incubation time, showing that BEVA binds to the dsDNA but no DNA oxidative damage was detected electrochemically. Non denaturing agarose gel-electrophoresis experiments were in agreement with the voltammetric results showing the formation of compact BEVA-dsDNA adduct. The dsDNA-electrochemical biosensor in incubated solutions showed that BEVA also undergoes structural modification upon binding dsDNA, and BEVA electroactive amino acid residues oxidation peaks were detected.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Bevacizumab; DNA damage; Glassy carbon; Interaction; Monoclonal antibody; Voltammetry; dsDNA-electrochemical biosensor

Mesh:

Substances:

Year:  2015        PMID: 26526907     DOI: 10.1016/j.aca.2015.09.049

Source DB:  PubMed          Journal:  Anal Chim Acta        ISSN: 0003-2670            Impact factor:   6.558


  2 in total

Review 1.  DNA Electrochemical Biosensors for In Situ Probing of Pharmaceutical Drug Oxidative DNA Damage.

Authors:  Ana-Maria Chiorcea-Paquim; Ana Maria Oliveira-Brett
Journal:  Sensors (Basel)       Date:  2021-02-05       Impact factor: 3.576

2.  DNA-Based Electrodes and Computational Approaches on the Intercalation Study of Antitumoral Drugs.

Authors:  Edson Silvio Batista Rodrigues; Isaac Yves Lopes de Macêdo; Giovanna Nascimento de Mello E Silva; Arthur de Carvalho E Silva; Henric Pietro Vicente Gil; Bruno Junior Neves; Eric de Souza Gil
Journal:  Molecules       Date:  2021-12-16       Impact factor: 4.411

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.